About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
VRTX - Vertex Pharmaceutica...| Previous Close | $238.64 | Open | $237.25 |
| Volume | 1.26M | Market Cap | 62.055B |
| Yield | Last Dividend |
| Vertex to Announce Fourth-Quarter 2020 F... | 01/22/21 |
| (Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Jan. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 20... | |
| Vertex to Announce Fourth-Quarter 2020 F... | 01/22/21 |
| BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February ... | |
| Vertex Pharmaceuticals Target Price $300... | 01/13/21 |
| Vertex Pharmaceuticals Target Price $300 Headline News | |
| STAT+: Vertex Pharma taking more aggress... | 01/11/21 |
| Vertex Pharmaceuticals is looking to acquire ???mid- and late-stage assets??? to bolster its current research pipeline, CEO Reshma Kewalramani said. | |
| Vertex to Present at the J.P. Morgan Hea... | 01/07/21 |
| (Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management wi... | |
| Vertex to Present at the J.P. Morgan Hea... | 01/07/21 |
| BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare... | |
| RBC Capital Stick to Their Buy Rating fo... | 12/09/20 |
| RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals | |
| Vertex Announces European Commission App... | 11/27/20 |
| LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the l... | |
| Odds Of Vertex's Pipeline Success Aren't... | 11/20/20 |
| Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) shares have come under selling pressure recently, given investor concern regarding diversity in th... | |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Ear... | 11/20/20 |
| Sanford C. Bernstein started coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report issued on Friday, The Fly reports. The br... | |
| Cystic fibrosis drug Trikafta could chan... | 11/18/20 |
| After a year of hesitation in the face of pending cost control guidelines, Vertex Pharmaceuticals has submitted Trikafta to Health Canada for approval... | |
| Vertex Recommends Rejection of ???Mini-T... | 11/13/20 |
| (Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been n... | |
| Global Autoimmune Disorder Therapies Mar... | 11/13/20 |
| DUBLIN--(BUSINESS WIRE)--The "Autoimmune Disorder Therapies: Global Markets" report has been added to ResearchAndMarkets.com's offering. The report wi... | |
| Vertex to Present at the Jefferies Virtu... | 11/12/20 |
| (Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Nov. 12, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management w... | |
| Vertex to Present at the Jefferies Virtu... | 11/12/20 |
| BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual Lond... | |
| Vertex Announces European Commission App... | 11/05/20 |
| LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the l... | |
| SVB Leerink Comments on Vertex Pharmaceu... | 10/24/20 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ??? Investment analysts at SVB Leerink raised their Q3 2020 earnings per share (EPS) estimates for s... | |
| SVB Leerink Analysts Boost Earnings Esti... | 10/24/20 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ??? Equities researchers at SVB Leerink upped their FY2020 earnings per share estimates for shares o... | |
| Vertex Pharmaceuticals Incorporated Expe... | 10/23/20 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ??? Research analysts at SVB Leerink upped their Q3 2020 earnings per share estimates for shares of ... | |
| Vertex Pharmaceuticals Incorporated (NAS... | 10/23/20 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ??? Analysts at SVB Leerink lifted their Q3 2020 earnings per share estimates for shares of Vertex P... | |
| FY2020 EPS Estimates for Vertex Pharmace... | 10/22/20 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ??? SVB Leerink boosted their FY2020 earnings per share (EPS) estimates for Vertex Pharmaceuticals i... | |
| Morgan Stanley Cuts Vertex Pharmaceutica... | 10/22/20 |
| Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target reduced by Morgan Stanley from $281.00 to $249.00 in a research report report published on M... | |
| $1.47 Billion in Sales Expected for Vert... | 10/21/20 |
| Wall Street brokerages predict that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will post $1.47 billion in sales for the current fiscal quarter,... | |
| Genetic Disorders Market to Grow at a CA... | 10/21/20 |
| Genetic Disorders Market is expected to register a healthy CAGR of 13.68% in the forecast period of 2019-2026. The report contains data from the base ... | |
| Orphan Drugs Market with (Covid-19) Impa... | 10/21/20 |
| Orphan drugs are specialized pharmaceutical agents that are administered for treatment of rare (orphan) diseases. These diseases have a very low preva... | |
| Vertex Pharmaceuticals Incorporated (NAS... | 10/20/20 |
| Wall Street brokerages predict that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will announce $2.35 earnings per share for the current fiscal qu... | |
| Vertex to Announce Third-Quarter 2020 Fi... | 10/19/20 |
| BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October ... | |
| Why Arrowhead Pharmaceuticals Is Trading... | 10/15/20 |
| Arrowhead Pharmaceuticals (NASDAQ: ARWR ) shares are trading higher on Thursday on news that Vertex Pharmaceuticals discontinued its trial of a drug c... | |
| Vertex Pharmaceuticals, Infosys leads pr... | 10/15/20 |
| Kaixin Auto (NASDAQ:KXIN) -34%. Fastly FSLY -29% after cutting guidance. Medalist Diversified REIT (NASDAQ:MDRR) -20%. VivoPower International VVPR -1... | |
| STAT Plus: Vertex, Amgen could be seekin... | 10/15/20 |
| Drug pipeline stumbles at Vertex Pharmaceuticals and Amgen could have both large-cap biotechs looking to make new deals. | |
| Hold rating | 01/19/21 |
| Morgan Stanley maintains Equal-Weight rating and raises Price Target from $249.00 to $251.00 | |
| Strong Buy rating | 11/30/20 |
| RBC Capital upgrades from Sector Perform to Outperform rating and announces Price Target of $267.00 | |
| Strong Buy rating | 11/20/20 |
| Bernstein initiates coverage with Outperform rating and announces Price Target of $275.00 | |
| Buy rating | 10/30/20 |
| SVB Leerink maintains Market Perform rating and lowers Price Target from $267.00 to $257.00 | |
| Strong Buy rating | 10/30/20 |
| Credit Suisse maintains Outperform rating and lowers Price Target from $292.00 to $285.00 | |
| Buy rating | 10/28/20 |
| UBS initiates coverage with Buy rating and announces Price Target of $287.00 | |
| Date | 2020-10-29 (AMC) | Est. (EPS/Rev.) | $2.32/ 1.47B |
| Actual (EPS/Rev.) | $2.64/ $1.54 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Lewis Aung's long pick | Kyaw Aung | 69.00 % | Subscribe |
| TopFlight Trades - Premium (Options) | Eric Cunningham | 51.00 % | Follow |
| Symmetry Options | Symmetry Options | 33.00 % | Follow |
| Optioneering-W | Sam Allen | 30.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
